New Medical Trial Asks: Fluids or Vasopressors First in Shock Treatment?

A new clinical trial has put one of emergency medicine’s long-running debates to the test. The ARISE FLUIDS trial looked at whether giving patients vasopressors (drugs that tighten blood vessels and raise blood pressure) early in treatment produces better results than using larger volumes of intravenous fluids during haemodynamic resuscitation (the process of restoring stable blood flow in a patient who is critically unwell).

The findings were published by the New England Journal of Medicine (NEJM), one of the world’s most widely read medical journals, and summarised in a video produced in partnership with Dr Glaucomflecken — a medic known for explaining complex clinical topics in accessible terms.

The trial sits squarely in the territory where cardiology (heart and circulation medicine) and nephrology (kidney medicine) overlap — two specialities that don’t always agree on how much fluid a sick patient should receive. Too little and blood pressure stays dangerously low; too much and the kidneys and lungs can suffer.

According to NEJM, the trial examined whether haemodynamic resuscitation guided by early vasopressor use could affect patient outcomes compared with a more fluid-generous approach. The precise results and any mortality or organ-function figures are contained in the full published trial; readers should consult the journal directly for the complete data.

For patients in Kent treated in intensive care or emergency departments — including those at East Kent Hospitals NHS Foundation Trust or Maidstone and Tunbridge Wells NHS Trust — decisions about fluid versus vasopressor management are made by specialist clinical teams based on individual assessment and the latest evidence. This trial may inform future clinical guidelines, though any changes to local practice would follow review by NHS bodies.

If you have concerns about a medical condition or emergency care, call NHS 111 for non-urgent advice or 999 in an emergency.